竞赛(生物学)
产业组织
仿制药
业务
过程(计算)
市场结构
制药工业
经济
营销
微观经济学
风险分析(工程)
药品
计算机科学
生物技术
医学
精神科
操作系统
生物
生态学
作者
Yixin (Iris) Wang,Jun Li,Ravi Anupindi
出处
期刊:Management Science
[Institute for Operations Research and the Management Sciences]
日期:2022-04-26
标识
DOI:10.1287/mnsc.2022.4423
摘要
Understanding the drivers of market concentration in the generic pharmaceutical industry is essential to guaranteeing the availability of low-cost generics. In this paper, we develop a structural model to capture the multiple determinants governing manufacturers’ entry decisions; in particular, we focus on how manufacturing complexity and the regulatory environment for generics approval affect concentration in drug markets. We estimate the model using data collated from six disparate sources. We find that manufacturing complexity, as reflected in the number of active ingredients, for example, significantly reduces the likelihood of generics entry. Moreover, the delay in the review process for the generics applications significantly affects the number of firms entering a market. Our policy simulations suggest that a shortened drug approval review time significantly increases the average number of entrants per market and reduces the fraction of markets with no generics entry; however, a notable portion of markets would still lack any generic competition. This paper was accepted by Jayashankar Swaminathan, operations management.
科研通智能强力驱动
Strongly Powered by AbleSci AI